TABLE 3.
Economic Analyses. Cost Estimates for Budget Impact Analysis, Years 2022/23 to 2026/27
| Baseline | Dapivirine Ring | Oral PrEP (65% Effectiveness) | ||
| 29% Effectiveness | 62% Effectiveness | |||
| Total cost of the HIV program* (2021 USD, millions) | 41.40 | 43.05 | 43.00 | 42.25 |
| Incremental cost (2021 USD, billions) | — | 1,650 (4%) | 1,598 (4%) | 850 (2%) |
| Total new HIV infections (millions) | 2.94 | 2.91 | 2.88 | 2.88 |
| HIV infections averted (thousands) | — | 27 (1%) | 60 (2%) | 63 (2%) |
| Total life years lost to AIDS (millions) | 36.02 | 35.94 | 35.85 | 35.84 |
| Life years saved (thousands) | — | 83 (0.2%) | 171 (0.5%) | 179 (0.5%) |
| Incremental cost per HIV infection averted (2021 USD) | — | 60,707 | 26,549 | 13,445 |
| Incremental cost per life year saved (2021 USD) | — | 19,985 | 9,337 | 4,741 |
| Threshold price of dapivirine ring | — | $4.25 | $8.82 | — |
*
Total cost of the HIV program includes the cost of antiretroviral treatment, inpatient care of those with HIV, palliative care, HIV testing (different modalities considered), condom distribution, medical male circumcision, postexposure prophylaxis (PEP), supply chain management, and pharmacovigilance costs.